Cryptococcosis is a fungal disease.It is caused by Cryptococcus neococcus, or Cryptococcus gattii.The disease is spread by inhaling a fungus linked to birds.It can infect animals and humans.It infects humans by inhaling fungus.The fungus mainly affects the lungs, but it can spread to the brain, called meningitis.Symptoms of the disease include - fever, headache, fatigue, dry cough and blurred vision.It can be treated by dozing off with amphotericin B, fluorocytosine and fluconazole.

Market Analysis and Insights: Global Cryptococcosis Drugs Market
The global Cryptococcosis Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cryptococcosis Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cryptococcosis Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cryptococcosis Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cryptococcosis Drugs market.

Global Cryptococcosis Drugs Scope and Market Size
Cryptococcosis Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cryptococcosis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Amphotericin B
Flucytosine
Fluconazole
Others

Segment by Application
Hospital Pharmacy
Retail Pharmacies
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott
Pfizer
Bristol-Mayers Squibb
Sigmapharm Laboratories
Novartis
Glenmark Pharmaceuticals